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Abstract
Background: Passion flower (Passiflora incarnata) is used in traditional medicine of Europe and
South America to treat anxiety, insomnia and seizure. Recently, it has shown antianxiety and
sedative effects in human.
Methods: In this study, anticonvulsant effects of hydro- alcoholic extract of Passiflora, Pasipay,
were examined by using pentylentetrazole model (PTZ) on mice. Pasipay, diazepam, and normal
saline were injected intraperitoneally at the doses 0.4–0.05 mg/kg, 0.5–1 mg/kg and 10 ml/kg
respectively 30 minutes before PTZ (90 mg/kg, i.p). The time taken before the onset of clonic
convulsions, the duration of colonic convulsions, and the percentage of seizure and mortality
protection were recorded. For investigating the mechanism of Pasipay, flumazenil (2 mg/kg, i.p) and
naloxone (5 mg/kg, i.p) were also injected 5 minutes before Pasipay.
Results: An ED50 value of Pasipay in the PTZ model was 0.23 mg/kg (%95 CL: 0.156, 0.342). Pasipay
at the dose of 0.4 mg/kg prolonged the onset time of seizure and decreased the duration of seizures
compared to saline group (p < 0.001). At the dose of 0.4 mg/kg, seizure and mortality protection
percent were 100%. Flumazenil and naloxone could suppress anticonvulsant effects of Pasipay.
Conclusion: It seems that Pasipay could be useful for treatment absence seizure and these effects
may be related to effect of it on GABAergic and opioid systems. More studies are needed in order
to investigate its exact mechanism.
Background
Epilepsy is one of the most common serious neurological
conditions. In contemporary society, the frequency and
importance of epilepsy can hardly be overstated from the
epidemiologic studies. However, in most studies, the
overall incidence of epilepsy in developed societies has
been found to be around 50 cases per 100,000 persons per
year, and rises steeply in older age [1,2]. The current ther-
apeutic treatment of epilepsy with modern antiepileptic
drugs (AEDs) is associated with side-effects, dose-related
and chronic toxicity, and teratogenic effects, and approxi-
mately 30% of the patients continue to have seizures with
current AEDs therapy [1,3].
Natural products from folk remedies have contributed sig-
nificantly in the discovery of modern drugs and can be an
alternative source for the discovery of AEDs with novel
structures and better safety and efficacy profiles [4]. Now,
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various phytochemical and pharmacological studies have
been carried out on these anticonvulsant plants [5]. More-
over, the number of patients and medical practitioners in
the industrialized world which use herbal medicines as a
supplement to or substitute for prescription drugs are
increased. Herbal medicines are often considered to be a
gentle and safe alternative to synthetic drugs. More than
half of the medically important pharmaceutical drugs are
either natural products or derivatives of natural products
[6-8]. In recent years, some experimental studies have
indeed evaluated Medieval Iranian medical remedies
using modern scientific methods. These studies raised the
possibility of revival of traditional treatments on the basis
of evidence-based medicine [9].
In Iran, several herbs have been used for anticonvulsant
effects from ancient times [10]. In Iran P. incarnata is pre-
pared by Iran Darouk Pharmaceutical Co. as the form of
tablet and drop with the name of Pasipay and is used in
the case of nervous disorder, anxiety, insomnia, muscular
tension.
The genus Passiflora consists of 500 species that are
mostly found in warm and tropical regions. Passiflora
comes from Latin word "Passio" that was first time discov-
ered by Spanish discoverers in 1529 and was described as
a symbol for "passion of Christ" [11,12]. This plant was
used widely in traditional medicine in West India, Mex-
ico, Netherland, South America, Italia and Argentina for
treatment of bronchitis, asthma, whooping cough, pneu-
monia and insomnia. It also has antianxiety, sedative,
antispasmodic and mild anti-microbial effects that are
known since long time [12]. One of species of this genus
named as Passiflora incarnata is more popular than its
other species in Europe and in homeopathic medicine; it
is used to treat insomnia and anxiety. Passiflora contains
several compounds including alkaloids, phenols, glycosyl
flavonoids and cyanogenic compounds [12]. In the some
experiments, it has potential effects for treatment of some
diseases like as anxiety, insomnia, attention- deficit hyper-
activity disorder, hypertension and cancer [13-18]. Also,
recent study showed that leaves of it had anticonvulsant
effects [19].
The effectiveness of Pasipay has been established in treat-
ing the physical symptoms of opioid withdrawal in
human [20]. But there was no report about the role of opi-
oid system for CNS depressant effects of Passiflora species.
Also, there were controversial reports about the role of
GABAergic system for CNS effects of it [21,22]. In this
study we examined anticonvulsant effects of Pasipay using
pentylenetetrazole (PTZ) induced seizure as petit mal epi-
lepsy model in mice. It was predicted that Pasipay would
show anticonvulsive effects in PTZ model, which may be
due to several mechanism. Thus, we elucidated the possi-
ble mechanisms underlying the actions of Pasipay on the




Male BALB/c mice (25–30 g) were obtained from the Razi
Institute (Karaj, Iran). The animals were individually
housed in colony rooms with 12/12 h light/dark cycle at
21 ± 2°C and had free access to food and water. All animal
experiments were carried out in accordance with the regu-
lations of the Ethics Committee of the Qazvin University
of Medical Sciences.
Plant material
Hydro- alcoholic extract of Pasipay was obtained from
Iran Darouk Pharmaceutical Co. (Tehran, Iran) which was
prepared from the standardized extract of leaves, flower
and fruit of P. incarnata. The total flavonoid content in
hydro- alcoholic extracts related to the dried plant mate-
rial was 4% (w/w) including vitexin and rutin.
Chemicals
Drugs used as follows: PTZ (Sigma), flumazenil ampoule
(2 mg/kg) (Roche), diazepam (Chemidaru, Iran),
naloxone (Tolid Daru, Iran). PTZ, diazepam and
naloxone were dissolved in normal saline. All compounds




The mice were divided into groups of ten animals each. In
the four groups, the mice were given Pasipay at the doses
(0.05, 0.1, 0.2, 0.4 mg/kg i.p.) 30 min before the admin-
istration of PTZ (90 mg/kg i.p). Two groups were injected
diazepam (0.5, 1 mg/kg i.p.) and one group was injected
normal saline 30 min before the administration of PTZ
(90 mg/kg i.p.) [23]. Each animal is placed into an indi-
vidual plastic cage for observation lasting 1 h. The onset
of a general clonus was used as the endpoint. The general
clonus was characterized by forelimb clonus followed by
full clonus of the body. The time taken before the onset of
clonic convulsions, the duration of clonic convulsions,
and the percentage of seizure and mortality protection
were recorded [23].
The effect of flumazenil on the anticonvulsant activity of Pasipay
We also studied the effects of a selective benzodiazepine
receptor antagonist, flumazenil on the anticonvulsant
activity of Pasipay in order to investigate the probable
involvement of benzodiazepine receptors [24]. It was
selected six groups of ten mice each. In the first group,
mice were given flumazenil (2 mg/kg) 5 min before the
administration of Pasipay (0.4 mg/kg) and 35 min beforeBMC Complementary and Alternative Medicine 2007, 7:26 http://www.biomedcentral.com/1472-6882/7/26
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the injection of PTZ. In the second group, the animals
received flumazenil (2 mg/kg) 5 min before the adminis-
tration of diazepam (0.5 mg/kg). Also, three groups were
injected diazepam (0.5 mg/kg i.p.), flumazenil (2 mg/kg)
and normal saline 30 min before the administration of
PTZ (90 mg/kg i.p.) respectively [23-26]. The anticonvul-
sant activity of Pasipay and diazepam in mice pretreated
with flumazenil was assessed and compared with normal
saline (10 ml/kg), flumazenil (2 mg/kg), diazepam (0.5
mg/kg) and Pasipay (0.4 mg/kg) treated animals.
The effect of naloxone on the anticonvulsant activity of Pasipay
It was selected four groups of ten mice each for further
investigation the probable modulatory activities of opioid
receptors on the anticonvulsant activity of Pasipay
[27,28]. It was applied naloxone as an opioid receptor
antagonist at a dose of (5 mg/kg) 5 min before the admin-
istration of Pasipay (0.4 mg/kg) and 35 min before the
injection of PTZ in group of ten mice each [23-26]. The
anticonvulsant activity of Pasipay in groups pretreated
with naloxone was assessed and compared with animals
pretreated only with Pasipay (0.4 mg/kg), naloxone (5
mg/kg) and normal saline (10 ml/kg) groups.
Statistical analysis
The dose of Pasipay to produce an anticonvulsant (ED50)
effect in 50 % of animals and its associated 95% confi-
dence limits was calculated by Litchfield and Wilcoxon
methods (PHARM/PCS Version 4). The data were
expressed as mean values ± S.E.M. and tested with one-
way ANOVA followed by the multiple comparison test of




An ED50 value of Pasipay in the PTZ model was 0.2 mg/kg
(%95 CL: 0.156, 0.342). Pasipay at the dose of 0.4 mg/kg
prolonged the onset time of seizure and decreased the
duration of seizures compared to saline group (p < 0.001)
(Table 1). Pasipay at the dose of 0.2 mg/kg only pro-
longed the onset time of seizure, compared to saline
group (p < 0.001) (Table 1). As it is shown in Table 1,
Pasipay exhibited its protection against seizure in a dose-
dependent manner. Furthermore, diazepam prolonged
the latency and shortened the duration of seizures com-
pared to saline group (Table 1).
The effect of flumazenil on the anticonvulsant activity of 
Pasipay
In the PTZ-induced seizure model, the administration of
flumazenil (2 mg/kg) 5 min before Pasipay (0.4 mg/kg)
reversed the effect of Pasipay in prolonging seizure latency
and reducing the duration of clonic seizures. There was no
significant difference between the latency and duration of
seizure in mice which received Pasipay (0.4 mg/kg) pre-
treated with flumazenil and the saline group. Also, fluma-
zenil could reverse the anticonvulsant activity of
diazepam (Table 2).
The effects of naloxone on the anticonvulsant activity of 
Pasipay
Pretreatment of mice with naloxone (5 mg/kg) 5 min
before the administration of the Pasipay (0.4 mg/kg)
reversed the reduction in seizure duration. However, the
time course of the seizure threshold in mice was not
reversed completely by naloxone and it was significant
compared to control (p < 0.001) (Table 3).
Discussion
The present study investigated the anticonvulsant effect of
Pasipay using the PTZ-model. Pasipay could suppress
onset and duration of clonic seizure in PTZ model and it
seems that this effect increased dose dependently. Also
seizure and mortality protection percent increased dose
dependently as we could observe that at the dose of 0.4
mg/kg, all animals were protected against seizure and
mortality significantly and this effect was similar to
diazepam 1 mg/kg.
This study is in agreement with a recent report by Dhawan
et al, however, we have seen anticonvulsant effects of
Table 1: Effects of Pasipay on PTZ-induced convulsion in mice
Treatment (dose) Onset (sec) Duration (sec) Seizure protection (%) Mortality protection 
(%)
Normal saline (10 ml/kg) 51.83 ± 64 12 ± 1.80 0 0
Diazepam (0.5 mg/kg) 485.5 ± 74.97*** 3.5 ± 2.21* 80 90
Diazepam (1 mg/kg) 600 ± 0*** 0 ± 0*** 100 100
Pasipay (0.05 mg/kg) 56 ± 4.51 15.3 ± 4.48 0 0
Pasipay (0.1 mg/kg) 112.66 ± 16.2 7.1 ± 2.5 10 50
Pasipay (0.2 mg/kg) 137.6 ± 17.8*** 7 ± 1.1 20 80
Pasipay (0.4 mg/kg) 600 ± 0*** 0 ± 0*** 100 100
Normal saline, diazepam and Pasipay were administered i.p. 30 min before the injection of PTZ (90 mg/kg, i.p.); Values are the mean ± S.E.M. for 10 
mice. *p < 0.05;*** p < 0.001, compared to saline group, Tukey-Kramer test.BMC Complementary and Alternative Medicine 2007, 7:26 http://www.biomedcentral.com/1472-6882/7/26
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extract at the lower doses. This could be explained by sev-
eral reasons: Our extract was the standard hydroalcoholic
extract of aerial parts of herb which was prepared as the
drug formulation, Pasipay, by Iran Darouk Pharmaceuti-
cal Co. But, the previous work was the methanolic extract
of the leaves of Passiflora incarnata [19]. Moreover, there
are several controversial reports about the CNS effects of
P. incarnata extracts and their active component which
could be related to different active component of it [29-
33]. Meanwhile, in our study, the major flavonoids of
Pasipay were also different from previous studies. In addi-
tion, there is a different between the sources of P. incarana
of our work and previous work.
Clonic seizure was induced by γ-aminobutyric acid
(GABA) transmission blocker PTZ [34]. Regarding the
possible contribution of GABAergic system in the anticon-
vulsant activity of Pasipay, flumazenil, a benzodiazepine
receptor antagonist, was used [24]. As it was shown in
table 2, flumazenil decreased the prolongation of seizure
latency induced by Pasipay and it also antagonized the
effect of Pasipay on decreasing the duration of clonic sei-
zures in the PTZ model. It is noteworthy that the anticon-
vulsant effect of Pasipay is blocked by an antagonist of
benzodiazepine receptor. So this effect of Pasipay seems
to be related to benzodiazepine receptor activation. This
result is similar to previous finding by Fernandez et al
[21]. They found that anxiolytic effects of one component
of Passiflora were related to benzodiazepine receptors
activation. However, there is a controversial study which
reported that anxiolytic effects of P. incarnata extract were
not mediated through an action on the benzodiazepine/
GABA receptors [22]. On the other hand, it is found that
many flavonoids could act as benzodiazepine- like mole-
cules in the central nervous system (CNS) and modulate
GABA-generated chloride currents in animal models of
anxiety, sedation and convulsion [21]. It is possible that
anticonvulsant activities of Pasipay related to its flavo-
noids like rutin and vitexin as was determined in the Pasi-
pay. Recently, rutin had sedative and sleep- enhancing
effects in mice [21]. However, there is a controversial
study which reported that pure vitexin and isovitexin of P.
incarnata had no activity in CNS tests [35]. Further studies
need to make clear which of these flavonoids or other
compounds have anticonvulsant effects.
We also found other mechanism about the anticonvulsant
effects of Pasipay. As it was shown in table 3, naloxone
only antagonized the effect of Pasipay on decreasing the
duration of clonic seizures in the PTZ model compared to
saline group. Naloxone decreased the prolongation of sei-
zure latency induced by Pasipay. However, it did not show
any significant reversal of Pasipay effects. It seems that
some part of anticonvulsant effects of it related to activa-
tion of opioid system which was attenuated by naloxone.
Since, one study reported that concurrent co-administra-
tion of benzoflavon moiety of P. incarnata with morphine
attenuated naloxone-precipitated withdrawal jumps [12].
Thus, we used naloxone as a non-specific opioid receptor
antagonist for preliminary study to clear the exact mecha-
nism of this herb.
On the other hand, anticonvulsant activity of kappa opi-
oid receptor (KOPr) agonists has been established in wide
range of previous animal studies. KOPr agonists are effec-
tive against bicuculline-, maximal electroshock- and exci-
Table 3: Effect of naloxone on the anticonvulsant activity of Pasipay in PTZ-induced convulsion in mice
Treatment (dose) Onset (sec) Duration (sec) Mortality protection (%)
Normal saline (10 ml/kg) 51.83 ± 64 12 ± 1.80 0
Naloxone (5 mg/kg) 10.66 ± 0.66 49.6 ± 4.34 0
Pasipay (0.4 mg/kg) 600 ± 0*** 0 ± 0*** 100
Pasipay+ Naloxone 125.4 ± 2.87*** 8.81 ± 2.64 40
Normal saline and Pasipay were administered (i.p.) 30 min before the injection of PTZ (90 mg/kg, i.p.); Naloxone was administered 35 min before 
the injection of PTZ (90 mg/kg, i.p.); Values are the mean ± S.E.M. for 10 mice; *** p < 0.001, compared to saline group, Tukey-Kramer test.
Table 2: Effect of flumazenil on the anticonvulsant activity of Pasipay and diazepam in PTZ-induced convulsion in mice
Treatment (dose) Onset (sec) Duration (sec) Mortality protection (%)
Normal saline (10 ml/kg) 51.83 ± 64 12 ± 1.80 0
Flumazenil (2 mg/kg) 44.71 ± 1.44 8.25 85
Diazepam (0.5 mg/kg) 485.5 ± 74.97*** 3.5 ± 2.21* 90
Diazepam+ Flumazenil 152.5 ± 28.9 12.25 ± 3.42 70
Pasipay (0.4 mg/kg) 600 ± 0*** 0 ± 0*** 100
Pasipay+ Flumazenil 184.33 ± 29.1 11 ± 1.52 50
Normal saline, diazepam and Pasipay were administered (i.p.) 30 min before the PTZ (90 mg/kg, i.p.); Flumazenil was administered 35 min before the 
injection of PTZ (90 mg/kg, i.p.); Values are the mean ± S.E.M. for 10 mice; *p < 0.05; ***p < 0.001, compared with saline group, Tukey-Kramer test.BMC Complementary and Alternative Medicine 2007, 7:26 http://www.biomedcentral.com/1472-6882/7/26
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tatory amino acid-induced convulsions. Furthermore,
they attenuate the kindling of seizures produced by
repeated administration of PTZ [36-39]. Furthermore,
dynorphine, an endogenous opioid peptide, binds to
KOPr. It has anticonvulsant effects in previous studies
[28]. There is one hypothesis that Pasipay could active
KOPr and produce protective effects against PTZ-induced
seizure. However, the mechanism of anticonvulsant
effects with KOPr agonist, have not been universal. Mod-
ulatory effects of its agonist on seizure induced by GABAA
receptor antagonists were reported [36]. Furthermore, its
agonist could inhibit glutamate release [40,41]. Thus,
there are two possibilities which could explain the anti-
convulsant activity of the Pasipay via the KOPr activation:
1) enhancement GABAergic activity or 2) attenuation
glutamatergic activity.
Conclusion
In brief, the present study provides evidence for anticon-
vulsant activity of Pasipay in the clonic seizure of PTZ
model. As the protective effects of Pasipay in clonic sei-
zure it suggests that it could be useful for treatment of
absence seizure. Furthermore, the important role of ben-
zodiazepine receptor in the effects of Pasipay should be
considered.
Also, the opioid receptor mechanism is apparently
involved in the response induced by Pasipay which
should be investigated.
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